NCT01037179View on ClinicalTrials.gov

An Open-Label, Long-Term Study With AL-4943A Ophthalmic Solution, 0.2% in Patients With Allergic Conjunctivitis

PHASE3CompletedINTERVENTIONAL
Enrollment

110

Participants

Timeline

Start Date

February 28, 2010

Primary Completion Date

May 31, 2010

Study Completion Date

May 31, 2010

Conditions
Allergic Conjunctivitis
Interventions
DRUG

Olopatadine Hydrochloride Ophthalmic Solution, 0.2%

Trial Locations (1)

532-0003

Investigational Center, Osaka

Sponsors

Lead Sponsor

Alcon Research
All Listed Sponsors
lead

Alcon Research

INDUSTRY